Apogee Therapeutics (APGE) to Release Earnings on Tuesday

Apogee Therapeutics (NASDAQ:APGE) will likely be issuing its quarterly earnings data before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($0.94) per share for the quarter.

Apogee Therapeutics Trading Down 3.4 %

NASDAQ:APGE opened at $33.37 on Tuesday. Apogee Therapeutics has a 12-month low of $32.46 and a 12-month high of $72.29. The stock has a fifty day moving average price of $41.56 and a 200 day moving average price of $47.75.

Wall Street Analysts Forecast Growth

APGE has been the topic of a number of recent analyst reports. Canaccord Genuity Group initiated coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 price objective on the stock. Wedbush increased their target price on Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a report on Monday, December 2nd. Canaccord Genuity Group started coverage on Apogee Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $89.00 price objective on the stock. Finally, Guggenheim reissued a “buy” rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $89.71.

Insiders Place Their Bets

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $40.58, for a total value of $608,700.00. Following the transaction, the chief executive officer now directly owns 1,302,987 shares in the company, valued at approximately $52,875,212.46. The trade was a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Carl Dambkowski sold 3,520 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $40.69, for a total transaction of $143,228.80. Following the completion of the sale, the insider now directly owns 252,623 shares of the company’s stock, valued at $10,279,229.87. The trade was a 1.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 63,810 shares of company stock valued at $2,903,556 over the last quarter. Company insiders own 36.10% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.